Literature DB >> 22001392

AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.

Tasneem Motiwala1, Nicola Zanesi, Jharna Datta, Satavisha Roy, Huban Kutay, Allyn M Checovich, Mohamed Kaou, Yiming Zhong, Amy J Johnson, David M Lucas, Nyla A Heerema, John Hagan, Xiaokui Mo, David Jarjoura, John C Byrd, Carlo M Croce, Samson T Jacob.   

Abstract

We previously demonstrated that the gene encoding PTPROt, the truncated form of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, is a candidate tumor suppressor and is down-regulated in chronic lymphocytic leukemia (CLL). Here, we show that PTPROt expression is significantly reduced in CD19(+) spleen B cells from Eμ-T cell leukemia 1 (TCL1) transgenic mice relative to the wild-type mice. Strikingly, as much as a 60% decrease in PTPROt expression occurs at 7 weeks independently of promoter methylation. To elucidate the potential mechanism for this early suppression of PTPROt in these mice, we explored the role of activating protein-1 (AP-1) in its expression. We first demonstrate that AP-1 activation by 12-O-tetradecanoylphorbol-13-acetate induces PTPROt expression with concurrent recruitment of c-fos and c-jun to its promoter. The PTPROt promoter is also responsive to over- and underexpression of AP-1, confirming the role of AP-1 in PTPROt expression. Next, we demonstrate that TCL1 can repress the PTPROt promoter by altering c-fos expression and c-jun activation state. Finally, using primary CLL cells we have shown an inverse relationship between TCL1 and PTPROt expression. These findings further substantiate the role of TCL1 in PTPROt suppression and its importance in the pathogenesis of CLL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001392      PMCID: PMC3234669          DOI: 10.1182/blood-2011-01-323147

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation.

Authors:  S Majumder; K Ghoshal; Z Li; Y Bo; S T Jacob
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

2.  Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.

Authors:  A H Kim; G Khursigara; X Sun; T F Franke; M V Chao
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.

Authors:  Kalpana Ghoshal; Jharna Datta; Sarmila Majumder; Shoumei Bai; Xiaocheng Dong; Mark Parthun; Samson T Jacob
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC.

Authors:  Hui C Wen; Wan C Huang; Adnan Ali; James R Woodgett; Wan W Lin
Journal:  Cell Signal       Date:  2003-01       Impact factor: 4.315

5.  BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia.

Authors:  L Pasqualucci; A Neri; L Baldini; R Dalla-Favera; A Migliazza
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Authors:  Roberta Bichi; Susan A Shinton; Eric S Martin; Anatoliy Koval; George A Calin; Rossano Cesari; Giandomenico Russo; Richard R Hardy; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

7.  Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor.

Authors:  Paula Monje; Maria Julia Marinissen; J Silvio Gutkind
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

Authors:  Yuri Pekarsky; Alexey Palamarchuk; Vadim Maximov; Alexey Efanov; Natalya Nazaryan; Urmila Santanam; Laura Rassenti; Thomas Kipps; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

9.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.

Authors:  Y Pekarsky; A Koval; C Hallas; R Bichi; M Tresini; S Malstrom; G Russo; P Tsichlis; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.

Authors:  M G Narducci; E Pescarmona; C Lazzeri; S Signoretti; A M Lavinia; D Remotti; E Scala; C D Baroni; A Stoppacciaro; C M Croce; G Russo
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

View more
  11 in total

Review 1.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

2.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Authors:  Lapo Alinari; Kiran V Mahasenan; Fengting Yan; Vrajesh Karkhanis; Ji-Hyun Chung; Emily M Smith; Carl Quinion; Porsha L Smith; Lisa Kim; John T Patton; Rosa Lapalombella; Bo Yu; Yun Wu; Satavisha Roy; Alessandra De Leo; Stefano Pileri; Claudio Agostinelli; Leona Ayers; James E Bradner; Selina Chen-Kiang; Olivier Elemento; Tasneem Motiwala; Sarmila Majumder; John C Byrd; Samson Jacob; Said Sif; Chenglong Li; Robert A Baiocchi
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

Review 3.  Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Authors:  John C Byrd; Jeffrey J Jones; Jennifer A Woyach; Amy J Johnson; Joseph M Flynn
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 4.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Authors:  Yuri Pekarsky; Alessandra Drusco; Prasanthi Kumchala; Carlo M Croce; Nicola Zanesi
Journal:  Gene Expr       Date:  2015

5.  The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

Authors:  J Wakim; E Arman; S Becker-Herman; M P Kramer; E Bakos; I Shachar; A Elson
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

6.  Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate.

Authors:  Shu-hao Hsu; Tasneem Motiwala; Satavisha Roy; Rainer Claus; Mufaddal Mustafa; Christoph Plass; Michael A Freitas; Kalpana Ghoshal; Samson T Jacob
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

7.  T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways.

Authors:  Francesco Paduano; Eugenio Gaudio; Afua A Mensah; Sandra Pinton; Francesco Bertoni; Francesco Trapasso
Journal:  Front Oncol       Date:  2018-08-13       Impact factor: 6.244

Review 8.  Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells.

Authors:  Feiling Xie; Hongmei Dong; Hao Zhang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

9.  PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.

Authors:  T Motiwala; H Kutay; N Zanesi; F W Frissora; X Mo; N Muthusamy; S T Jacob
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

Review 10.  TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.

Authors:  A Bresin; L D'Abundo; M G Narducci; M T Fiorenza; C M Croce; M Negrini; G Russo
Journal:  Cell Death Dis       Date:  2016-01-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.